Denali Therapeutics Inc. (DNLI) › RevenueDenali Therapeutics Inc. (DNLI) — RevenueAnnual figures by period end, from SEC filings.2016-12-31: $02017-12-31: $02018-12-31: $129.10M2019-12-31: $26.32M2020-12-31: $335.56M2021-12-31: $48.66M2022-12-31: $105.06M2023-12-31: $330.53M2024-12-31: $02025-12-31: $0$02016-12-31Revenue (USD)2025-12-31Period endedRevenueChange YoYSource filing2025-12-31$0—2026-02-26From 2025-01-012024-12-31$0-100.0%2026-02-26From 2024-01-012023-12-31$330.53M+214.6%2026-02-26From 2023-01-012022-12-31$105.06M+115.9%2025-02-27From 2022-01-012021-12-31$48.66M-85.5%2024-02-28From 2021-01-012020-12-31$335.56M+1174.9%2023-02-27From 2020-01-012019-12-31$26.32M-79.6%2022-02-28From 2019-01-012018-12-31$129.10M—2021-02-26From 2018-01-012017-12-31$0—2020-02-27From 2017-01-012016-12-31$0—2019-03-12From 2016-01-01Other metrics: Cost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)